The estimated Net Worth of & Johnson Johnson & Johnson... is at least $212 Milión dollars as of 30 June 2020. Johnson owns over 725,000 units of Fusion Pharmaceuticals stock worth over $79,099,620 and over the last 20 years sold FUSN stock worth over $133,278,054.
has made over 16 trades of the Fusion Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently bought 725,000 units of FUSN stock worth $12,325,000 on 30 June 2020.
The largest trade 's ever made was selling 18,367,346 units of Fusion Pharmaceuticals stock on 20 November 2017 worth over $50,510,202. On average, trades about 1,155,708 units every 294 days since 2004. As of 30 June 2020 still owns at least 3,670,516 units of Fusion Pharmaceuticals stock.
You can see the complete history of Johnson stock trades at the bottom of the page.
's mailing address filed with the SEC is ONE JOHNSON & JOHNSON PLAZA410 GEORGE STREET, , NEW BRUNSWICKNEW BRUNSWICK, NJNJ, 0893308901.
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams a & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include: